New Medium to Boost and Optimise the Production of AAV in Sf9 Insect Cells Announced

Lonza announces the launch of the TheraPEAK™ SfAAV™ Medium, the first chemically defined, non-animal origin medium designed specifically for the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications. The new high-performance medium accelerates cell growth, increases productivity, and reduces process variability and costs, expediting time-to-market for safe, scalable, life-saving gene therapies. The unique benefits of the TheraPEAK™ SfAAV™ Medium, which marks the latest addition to Lonza’s TheraPEAK™ Family of cell culture media and reagents for cell and gene therapy applications, are summarised in an informative poster that can be downloaded for free from the Lonza website.

Lonza’s TheraPEAK™ SfAAV™ Medium has been explicitly designed to address this need, providing a cost and time efficient solution for the production of AAV in Sf9 insect cells. Allowing for rapid cell growth, the TheraPEAK™ SfAAV™ Medium reduces processing time significantly, enabling cell infection one day earlier than similar media available on the market, and boosting laboratory performance. Due to its chemically defined nature, the new hydrolysate free medium produces AAV that requires less purification, further decreasing the overall processing time and minimising labour requirements. Furthermore, the TheraPEAK™ SfAAV™ Medium supports consistent cell growth throughout all phases of the culturing process, considerably reducing process variability. 

As a chemically defined, non-animal origin product, the TheraPEAK™ SfAAV™ Medium is safer to use than media containing animal or human components, thereby facilitating regulatory compliance. Additionally, the medium is supplied with a US Food and Drug Administration drug master file, alleviating the relevant preparation and submission burden. 

More information online